Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Rasburicase for adults with acute tumor lysis syndrome: a review of clinical and cost effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions Rasburicase was found to lower uric acid levels in adult cancer patients who had, or were at risk for developing, hyperuricemia or tumour lysis syndrome (TLS). Rasburicase was found to be well tolerated in adult cancer patients, with a low rate of adverse events, renal failure, or need for hemodialysis. No evidence on the cost effectiveness of rasburicase compared with allopurinol or hydration for adults with acute TLS was identified. Indexing Status Subject indexing assigned by CRD MeSH Adult; Cost-Benefit Analysis; Humans; Tumor Lysis Syndrome; Urate Oxidase Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000192 Date abstract record published 29/01/2014 |